CONGRESS - LSX Home Brochure.pdf · There is a whole host of benefits to downloading the app:...

1

The networkfor life scienceexecutive leaders

4-5 February, 2020 133 Houndsditch, Liverpool St

London, UK

6th Annual

#lsxworld @lsxleaders

WORLDCONGRESS

STRATEGY, INVE STME NT, PARTNERING & COMMERC IAL ISAT ION FOR L IFE SC IENCE

E X E C U TIVE LE AD ERS

Organised by:

Wi f i Ne twork : e tcvenues Password : w i f i 8020

Final programme correct as of 03.02.2020

32LSX World Congress 4-5 February 2020

#LSXWorld @lsxleaders

LSX World CongressWelcome

STRATEGY, INVESTMENT AND PARTNERING FOR LIFE SCIENCE EXECUTIVE LEADERS

Welcome to the LSX World Congress 2020! We’re delighted to be returning for the 6th annual edition of Europe’s leading executive strategy, partnering and investment congress. #LSXWorld 2020 is the biggest and best yet with 1,000 life science CXOs, investors, pharma heads and key stakeholders registered and more speakers, company showcases and partnering meetings than ever before!

Now encompassing the Medtech Leaders and three Biotech Leaders tracks - Capital Markets & Investment, Partnerships & Deal Making and Capital Deployment & Commercialisation Strategy as well as Inv¤$table and Lic¤n$able showcases, CEO and Pharma BD Leaders forums and workshops, the LSX World Congress is the all-encompassing strategy event that addresses all c-suite challenges and opportunities!

As always, we retain our relentless focus on quality peer-to-peer discussion, high-level networking and partnering, unique formats and a vetted, high-calibre audience to bring together the people that matter to the future of healthcare and life sciences.

The LSX World Congress Team

#LSXWorld www.lsxleaders.com/lsx-world-congress@LSXLeaders

Wifi: etcvenuesPassword: wifi8020

LSX World Congress 4-5 February 2020


Turbocharge your onsite experience

We’ve built a mobile app for LSX World Congress!

It has all the important information you’ll need for the event and features to enhance your onsite experience.

There is a whole host of benefits to downloading the app:

Personalise your onsite agenda

Set notifications for sessions you’re interested in

Book 1:1 meetings

Step 1: Download the App!

If you haven’t already, download the app on the deviceyou have with you today.

Search for “LSX Events” or LSX Events in the App storefor iOS phones, or Google Play store for Android phones.

Step 2: Log In Open up the app once downloaded and loginusing your name and the email you used whenregistering for the conference.

Step 3: Verify When prompted, enter the verification code sentto your email account (check all folders) and away you go.Any questions, please ask a member of the LSX Team.

Having problems with the App? Visit our information and help desk at the registration point and speak to Rebecca Herne, Operations Manager.



SILVER PARTNERS

SUPPORTING PARTNERS

GOLD PARTNERS

INVENTING FOR LIFE



Our PartnersPLATINUM PARTNERS

GOLD PARTNERS

76LSX World Congress Agenda - Day 1 4-5 February 2020


On Floor Showcases Showcase opportunities exist in the 2020 congress for companies looking to raise finance (Inv¤$table) and/or attract interest in a licensing deal (Lic¤n$able). These showcases are for all stages of private and public companies to present news and deal flow or pitch to an audience of active investors, pharma, Medtech commercial leaders and big tech. Inv¤$table and Lic¤n$able are 15-minute showcase slots allowing companies to deliver succinct, hard-hitting and insightful presentations to an audience seeking to uncover innovative research and/or technology for capital and strategic transactions, and licensing and R&D collaborations. Presenting company executives will present to a live audience, plus have their showcases video recorded and turned into a post-event strategic communications piece.

Satellite Forums Our extremely popular and always oversubscribed LSX Forums provide a unique, powerful and valuable space for the candid sharing of experiences, expertise and insight between industry peers. By invitation only, the four forums run throughout day one of the World Congress for Pharma BD heads, startup CEOs, private growth-stage CEOs and for publicly listed CEOs.

All forums are held under Chatham House Rule and include peer-review case studies from CEOs and co-host partners and a general discussion focused on brainstorming solutions to the collective challenges of the attendees.

LEADERS FORUMPHARMA BD

11:00Biotech Inv¤$table Showcase

INVENTING FOR LIFE

Co-hosted byCo-hosted by

11:00

11:00

11:15

11:30

11:45

12:00

a

a

P H A R M A C E U T I C A L S



a

step pharma step pharma

Hemispherian

Co-hosted by

ROOM: ONFLOOR SHOWCASE AREA ROOM: SYNERGY 2

ROOM: INTEGRATE 3

ROOM: BALCONY

Medtech Inv¤$table Showcase Lic¤n$able Showcase

LSX World Congress Agenda - Day 1 4-5 February 2020

www.lsxleaders.com/lsx-world-congress

Welcome Address

Josh Dance, SVP, LSX

Keynote Panel: A sustainable connected European ecosystem: Building and strategically financing long-term sustainable Biotechs and life science clusters

Moderator: Clive Cookson, Science Editor, Financial TimesOnno van de Stolpe, CEO, GalapagosDebbie Harland, Partner, SR One Craig Johnstone, COO, Evotec Geraldine O’Keeffe, Partner Public Equities, LSPSean Marett, Chief Business and Chief Commercial Officer, BioNTech Tim Luker, Sr. Director External Innovation, Lilly

Panel: Value-based pricing and advanced therapies

Track Keynote Panel: New capital, syndication and capital alignment to build the European ecosystem

Track Keynote Panel: Building cross-industry and cross geography partnerships across Europe’s Biotech clusters and beyond

Morning Break

Capital Deployment & Commercialisation Strategy

Capital Markets & Investment Partnerships & Deal Making

Moderator: William Hicks, Co-chair of Securities & Capital Markets Practice Group, Mintz Tim Luker, Sr. Director Ext. Innovation, LillyGraziano Seghezzi, Managing Partner, Sofinnova Sander Slootweg, Managing Partner, Forbion Capital Partners Bibhash Mukhopadhyay, Principal, New Enterprise Associates Sofia Ioannidou, Partner, Andera Partners

Moderator: Robert Gebhardt, MD, PharmaVentures Jordi Naval, CEO, Biocat Søren Bregenholt, Chairman of the Board, Medicon Valley Alliance Michael Altorfer, CEO, Swiss Biotech Association Annemiek Verkamman, Managing Director, HollandBIO

Moderator: Thomas Lönngren, Former head of EMA, NDAJason Ward, Group Director, Innovation & Strategy, Oncology Market Access & Pricing, AstraZeneca Francis Pang, VP Global Market Access, Orchard Therapeutics Mathias Flume, Head of Department, KVWL

Presentation: EMA Support to SMEs & Innovation Constantinos Ziogas, Head of SME Office, European Medicines Agency

Fireside Chat: VC to DC - A new model for pension fund allocation to life science venture capital?

Moderator: William Hicks, Co-chair of Securities & Capital Markets Practice Group, Mintz Alice Hu Wagner, Managing Director, British Business Bank

CEO Fireside Chat: Preparing EU Companies for international acquirers

Moderator: Jonathan Gertler, Managing Partner & CEO, Back Bay Advisors Kate Bingham, Managing Partner, SV Health Investors

9:00

9:10

10:30

Welcome Address

Kiron Campbell, Conference Director, LSX

Keynote Panel: M&A, consolidations, new value propositions, and commercial leadership in Medtech

Moderator: Robbie McLaren, Partner, Latham & Watkins Charity Kufaas, VP Strategy & Business Development EMEA, MedtronicHani Abouhalka, Company Group Chairman - Medical Devices EMEA, Johnson & Johnson Rupert Winckler, Head of EMEA New Business Development, Olympus

Keynote Panel: Unpacking value-based healthcare and multi-stakeholder led value creation

Moderator: Stephen Dorrell, Chairman, Dorson and LaingBuisson Frank Maddux, Global CMO,Fresenius Medical Care Maarten Akkerman, Vice President Medical Affairs and Value-Based Healthcare, Medtronic John E Milad, CEO, Quanta Dialysis Richard di Benedetto, President and EVP, Aetna International

Keynote Investment Panel: The peaks and troughs of the Healthtech investment landscape

Moderator: Mark Andrews, Managing Director, Pharma Ventures Anat Naschitz, Managing Director, OrbimedMartin Pfister, Senior Investment Manager, High-Tech Gründerfonds Caroline Gaynor, Vice President, Lightstone Ventures Alessio Beverina, General Partner, Panakès Partners Arnd Kaltofen, Partner, VI Partners

11:00

Fireside Chat: IPO case study: Making a mark on Europe’s public markets

Moderator: Tina Tan, Executive Editor, FirstWord Medtech Ian Crosbie, CEO, Sequana Medical

Keynote Presentation: Where’s the money going? Capital Markets Outlook

Ben Thorpe, Head of Healthcare Banking EMEA, Goldman Sachs

10:10

11:00 11:00 11:00

Medtech Leaders

11:00

11:45 11:45 11:50 11:40

9:00

9:05

9:45

ROOM: ENTERPRISE 2 ROOM: INTERACT

ROOM: ENTERPRISE 2 ROOM: SYNERGY 1 ROOM: ENGAGE ROOM: INTERACTINNOVATIONZONE


This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge.




Biotech Inv¤$table Showcase13:45

Lunch Break12:45

13:45


Biotech Inv¤$table ShowcaseLEADERS FORUMPHARMA BD

LEADERS FORUMPHARMA BD

12:15

12:30

13:45

14:00

14:15

14:30

14:45

15:00

15:15

15:30

Medtech Inv¤$table Showcase

Co-hosted by

15:45


ROOM: ONFLOOR SHOWCASE AREA ROOM: SYNERGY 2

ROOM: INTEGRATE 3

ROOM: BALCONY

ROOM: SYNERGY 2

Cardio Metabolic

T H E R A P E U T I C S

L E M P O



Panel: Attracting the big strategics; what CVC need to see

Moderator: Elizabeth Cairns, Reporter, Vantage Jonathan Goldstein, Director, Corporate Research and Ventures, Boston Scientific Assaf Barnea, CEO, Sanara Ventures Jeanne Bolger, VP Venture Investments, Johnson & Johnson Innovation Andreas Wuepper, Director Investments, Europe, Fresenius Medical Care Ventures

Lunch Break12:45

Panel: Go big or go home? - evolving early investment strategies

Moderator: Lisa Urquhart, Editor, Vantage Roger Franklin, Partner, Hadean Ventures Sara Secall, Partner, INVEREADY Montserrat Vendrell, General Partner, Alta Life Sciences Søren Lemonius, Managing General Partner, Sunstone Life Science Ventures Søren Møller, Managing Partner, Novo Seeds

Panel: Positioning public partnerships - optimising deal-making when listed

Moderator: Cody Powers, Associate Principal, ZS Renée Aguiar-Lucander, CEO, Calliditas Therapeutics Olav Hellebo, CEO, ReNeuron John Strafford, VP, Head of BD, Silence Therapeutics John Dawson, CEO, Oxford BioMedica

Panel: Harnessing the drivers for success in your early stage programme

Moderator: Carl Engleman, Vice President, Cello Health ConsultingCaroline Barelle, CEO, ElasmogenStuart Collinson, CEO, Oxstem Lars van der Veen, COO, iOnctura

Fireside Chat: Building A(I), and deploying A big B Moderator: John Hodgson, Independent Consultant Tim Guilliams, CEO, Healx

Fireside Chat: An A+ mega round launch

Moderator: Lisa Urquhart, Editor, Vantage Mark Altmeyer, CEO, Arvelle Therapeutics

Fireside Chat: Going with your gut in Pharma co-development

Moderator: Lucie Ellis, Managing Editor, In Vivo Simon Baeriswyl, COO, Enterome

Panel: Making the grade - B+ rounds and investor alignment

Moderator: Jonathan Gertler, Founder & CEO, Back Bay Life Science Advisors Hakan Goker, Executive Investment Director, M Ventures Giovanni Mariggi, Partner, Medixci Jack Nielsen, MD, Vivo Capital Thibaut Roulon, Investment Director - Life Sciences, Bpifrance Clara Campàs, Partner, Asabys Partners

Fireside Chat: Crafting win/win early-stage Biotech-to-Biotech partnerships Moderator: Lucie Ellis, Managing Editor, In Vivo Cedric Ververken, CEO, Confo Therapeutics

Panel: Early planning and effective capital deployment when progressing through the clinic

Moderator: John Hodgson, Independent Consultant Joe Dupere, CEO, Rexgenero Leon Hooftman, CMO, ISA Pharmaceuticals Grace E. Colón, CEO, InCarda Therapeutics Juho Jalkanen, CDO, Faron Pharmaceuticals

Afternoon Break15:30

Fireside Chat: Regulatory assistance for Europe’s life science SMEs

Moderator: Ben Howlett, Director, World Healthcare Journal Constantinos Ziogas, Head of SME Office, European Medicines Agency

Panel: Raising capital and diversity standards - addressing the imbalance

Moderator: Lucie Ellis, Managing Editor, In Vivo Kyp Sirinakis, Managing Partner, Epidarex Capital Roel Bulthuis, Managing Partner, Inkef Rafaèle Tordjman, Founder & CEO, Jeito Maina Bhaman, Partner, Sofinnova Fiona de Hemptinne, Venture Partner, UCB Ventures

Panel: Passing the baton - Success in M&A deal-making

Moderator: Gregory Benning, Managing Director, Head of Investment Banking, Back Bay Life Science Advisors Luc Dochez, Co-founder, Pharvaris and former CEO, Tusk Therapeutics Phil L’Hullier, Head of BD, Europe, European Innovation Hub, MSD Andy Staples, Head of Deal Finance, AstraZeneca

Panel: Commercial Success in Medtech through talent and team building Moderator: Kristien Esser, CEO, Guided SolutionsCraig Marshall, CEO, OrganOxChristoph Ruedig, Partner, Albion Capital Simon Hubbert, Chairman, Rhythm AI Brian Howlett, Non-Exec. Director, Accentus Medical, Angle, Oxford Endovascular Maina Bhaman, Partner, Sofinnova

Panel: Together we rise; tips and tricks for Healthtech partnerships

Moderator: Roy Wiesner, Managing Director, aMoon Fund Brian Hakim, Director of BD, MedTecX Seamus Browne, Head of Industry Partnerships, Royal College of Surgeons Sascha Alilovic, Partner, SHS Capital John Power, CEO, Aerogen

12:05 12:05 12:10 12:05

13:45 13:45 13:45 13:45

14:25 14:35 14:25 14:20

14:45 15:00 14:45 14:55

Panel: Learnings and lessons from early-stage fundraising success stories

Moderator: Todd Usen, CEO, Activ Surgical Mark-Jan Harte, CEO, Aidence Ian Wilson, CEO, ImaginAb Rainer Strohmenger, Managing Partner, Wellington Partners Ena Prosser, Partner, FH Partners

ROOM: ENTERPRISE 2 ROOM: SYNERGY 1 ROOM: ENGAGE ROOM: INTERACT

INVENTING FOR LIFE

INNOVATIONZONE

INNOVATIONZONE





ROOM: INTEGRATE 3

ROOM: BALCONY


Biotech Inv¤$table Showcase

INVENTING FOR LIFE


16:00 16:00

16:00

16:15

16:30

16:45

17:00

17:15

17:30 In4DermBecause Skin Matters


ROOM: ONFLOOR SHOWCASE AREAROOM:

SYNERGY 2ROOM:

BALCONY


Panel: Key Learnings from the M&A Market

Moderator: Mark Andrews, Managing Director, Pharma Ventures Peter Ullrich, CEO, Titan Spine Eline Vrijland-Van Beest, Co-Founder, Nightbalance Chas Taylor, CEO, Veryan Medical Vanessa Vankerckhoven, CEO and Co-Founder, Novosanis Andrew Glass, Regional Director Northern Europe, Abbott

17:45

Afternoon Keynote: Ad-vant-ages in building a Biotech family

Moderator: Melanie Senior, Analyst and Specialist Writer, Life SciencesMatthew Gline, CFO, Roivant Sciences

Afternoon Keynote Panel: In conversation with pharma leaders - Innovation, efficiency and technology convergence

Moderator: Ben Thorpe, Head of Healthcare Banking EMEA, Goldman Sachs Ivana Magovčević-Liebisch, CBO, Ipsen Nigel Sheail, Global Head of M&A and BD&L, NovartisPhilippe Lopes-Fernandes. SVP, Global Head of BD and Alliance Management, Merck KGaA Ben Thorner, SVP, Global Business Development, MSD

Closing Keynote Panel: R&D and the PRC - Regulatory reform, partnering and advancing development in China

Moderator: Sam Fazeli, Head of European Research, Pharmaceuticals Analyst, BloombergMirko Scherer, CEO, CoFeS China Zishan Haroon, Managing Partner, Julz Co Richard Yang, Director of Pharmacovigilance Operations, Fountain Medical Development Guillaume Vignon, SVP Business Development, BeiGeneDonald Xu, Managing Partner, Lynx Financial

16:00

Networking Party

18:30Investor Dinner If you have purchased a ticket to the Investor-only dinner, you will be directed from the conference venue at approx. 7pm to the dinner venue. Your badge will confirm you have a seat reserved. This dinner required pre-registration and is a sellout.

Panel: The making of Medtech leaders; from fundraising to upscaling

Moderator: Michael Branagan-Harris, CEO, Device Access UKMartin Frost, Founder & Non-Executive Director, CMR Surgical Bernard Ross, CEO, Sky Medical Technology Eliane Schutte, CEO, Xeltis Steve Swinson, Chair, Comphya and Tibbyah Holdings, Former Chair, Acteon, Vexim, Bone Therapeutics

Fireside Chat: Company building and the journey to acquisition

Moderator: Tina Tan, Executive Editor, FirstWord Medtech Peter Ullrich, CEO, Titan Spine

16:20

17:00

16:00

16:20

17:00


ROOM: EXHIBITION AREA

INNOVATIONZONE

#LSXWorld @lsxleaders #LSXWorld @lsxleaders

Biotech Inv¤$table Showcase

THERAPEUTICS

HOSTED BY:

17:45Networking Party

18:30Investor Dinner If you have purchased a ticket to the Investor-only dinner, you will be directed from the conference venue at approx. 7pm to the dinner venue. Your badge will confirm you have a seat reserved. This dinner required pre-registration and is a sellout.

ROOM: EXHIBITION AREA

HOSTED BY:



On Floor Showcases Showcase opportunities exist in the 2020 congress for companies looking to raise finance (Inv¤$table) and/or attract interest in a licensing deal (Lic¤n$able). These showcases are for all stages of private and public companies to present news and deal flow or pitch to an audience of active investors, pharma, Medtech commercial leaders and big tech. Inv¤$table and Lic¤n$able are 15-minute showcase slots allowing companies to deliver succinct, hard hitting and insightful presentations to an audience seeking to uncover innovative research and/or technology for capital and strategic transactions, and licensing and R&D collaborations. Presenting company executives will present to a live audience, plus have their showcases video recorded and turned into a post-event strategic communications piece.

Satellite Workshops The workshops are intimate 90-minute interactive education forums in which CXOs are navigated through considerations, strategy and ideas for approaching key company milestones by an expert partner. The workshops run throughout day two of the World Congress covering M&A, clinical strategies, licensing & collaboration and market access.

WORKSHOP

CLINICALSTRATEGIES

11:00Biotech Inv¤$table Showcase


11:00

Co-hosted by11:00

11:15

11:30

11:45

12:00

12:15

Current

Less Contrast

Inverse

Epigenetic Modulation for Cardiovascular Disease

12:30

ROOM: ONFLOOR SHOWCASE AREAROOM:

SYNERGY 2ROOM:

BALCONYROOM:

INTEGRATE 3



Welcome Address

Josh Dance, SVP, LSX

Keynote Panel: The listing consideration - building on roots or the American dream?

Moderator: Isabella Schidrich, Managing Director, Nasdaq Anthony Pagano, SVP Finance and Corporate Development, GenmabKevin Lee, CEO, Bicycle Therapeutics Sean Marett, Chief Business and Chief Commercial Officer, BioNTech Christophe Douat, CEO, MedinCell

Panel: Going it alone - Challenges and late-stage capital deployment in self-commercialisation

Moderator: Carl Engleman, Vice President, Cello Health ConsultingCarl Sterritt, CEO, Shield TherapeuticsErik van den Berg, CEO, AM-Pharma Eduardo Bravo, CEO, Nordic Nanovector Kieran Rooney, VP Strategic Alliances and Licensing, Amryt Pharma

Track Keynote Panel: China’s integration into global, the global pharma science and what this means for raising capital in Asia

Building a Biotech unicorn from scratch through partnerships

Morning Break

Capital Deployment & Commercialisation Strategy

Capital Markets & Investment Partnerships & Deal Making

Karen Liu, Partner, 3E BioVentures

Jens Hennecke, Chief Business Officer, SOTIO/PPF Group

Panel: New capital & growth - Asian investment into European life sciences

Panel: Are we there yet? Navigating the roadmap in early-stage partnerships

Moderator: Adrian Dawkes, Managing Director, PharmaVentures Tomas Landh, Inovation Sourcing Vice President, Senior Principal Scientist of Search and Evaluation, Novo Nordisk Sergio Capancioni, Director S&E Western Europe, AbbVie Catherine Pickering, CEO, iOnctura Rick Davis, Senior Director, New Ventures and Transactions, Oncology, Johnson & Johnson

9:25

9:35

10:30

Welcome Address

Kiron Campbell, Conference Director, LSX

Keynote Panel: Building the IOMT ecosystem; connected devices, refined commercial strategies

Moderator: Julie Bretland, CEO, Our Mobile Health Mathias Goyen, Chief Medical Officer Europe, GE Healthcare Patrik Sobocki, Investment Manager, Industrifonden Thomas Hummel, Head of Innovation and Strategy, Siemens Healthineers David Germonpré, Partner, MTIP Xavier Bertrand, VP Healthcare Services and Alliances Emea, Boston Scientific

Keynote Fireside Chat: New frontiers - Taking Asian Medtech global

Moderator: Summer Park, Senior Business Development Director, PharmaVenturesFrank Yu, CEO, Ally Bridge Group

Panel: Creating empowered, technologically enabled Healthtech consumers

Moderator: Michael Branagan-Harris, CEO, Device Access UKFrances A. Ayalasomayajula, Head of Population Health, HPRichard di Benedetto, President, AetnaSteve Atkinson, CEO, Atlantic Therapeutics Ben Maruthappu, CEO, Cera Victoria Betton, Founder, mHabitat, CIO, Mindwave Ventures

11:00

Panel: Successfully navigating regulatory change; strategies responses to MDR and IVDR

Moderator: Amanda Maxwell, European Reg. Affairs Director, Medtech Insight David Tuch, CEO, Lightpoint Medical Susana de Azevedo Wäsch, VP Quality Management & Regulatory Affairs, Ypsomed AG James Pink, Senior Director, NSF International Robert Abbott, VP, Chief Legal Counsel EMEA, Stryker Manuela Gazzard, Group Executive Director Regulatory Services Healthcare, BSI Group

Fireside Chat: Mapping, supporting and financing European innovation and entrepreneurship

Moderator: Ari Silverman, Partner, Mavie Technologies Katherine Cohen, Venture Partner, Panacea Venture Peter Bisgaard, Managing Director, Nan Fung Life Sciences Marietta Wu, Managing Director, Quan Capital Frank Yu, CEO, Ally Bridge Group

Moderator: Mick Cooper, Analyst, Trinity DeltaAdelaide Cracco, Head of Life Sciences, European Investment Fund

Fireside Chat: At the intersection of digitisation and value-based care Moderator: David Germonpré, Partner, MTIPRobbie Hughes, CEO, Lumeon

9:20

9:25

10:10

11:00 11:00 11:0011:00

11:20 11:20

12:00

11:40

12:00


Medtech Leaders


INVENTING FOR LIFE



Additional seats may be available on first-come first-served basis.


Additional seats may be available on first-come first-served basis.



Satellite Sessions

A Chatham House Rule, invite-only forum for CEOs, CFOs, CBOs and chairmen of listed life science and healthcare companies. The forum will feature peer-reviewed CEO and partner case studies, and an interactive general discussion.

The Public CEO Forum is open only to life sciences companies listed on the public markets. This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge.

Co-Hosts:

Timings: Feb 4, 11:00 - 12.45 - Synergy 2 Case Studies

Moderator:

Philip Broke, Partner, White & Case

Case Study 1: ESG & Changes in Regulatory Environment Assaf Homossany, MD-EMEA, Nasdaq

Case Study 2: PIPEs deals and preparing for a US Listing Philip Broke, Partner, White & Case

Case Study 3: Gilead/Galapagos Alliance

Onno Van de Stolpe, CEO, Galapagos

PUBLICCEO FORUM

A Chatham House Rule, invite-only forum for CEOs of life science and healthcare startups.

The forum will feature peer-reviewed c-level and partner case studies, and an interactive general discussion.

The Private CEO Forum is only open to pre-series A private biotechs and spinouts of our TTO partners. This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge.

Co-Hosts:

Timings: Feb 4, 16:00 - 17.45 - Synergy 2 Case Study Roundtable Moderated discussion: How to approach and build relationships with VCs

Nicholas Ibery, Member of the Investment Committee, NCL Technology VentureClaire Brown, Investment Director, BioCity

Term Sheet Workshop: Key VC terms and all you need to know on a term sheet.

James Baillieu, Partner, Bird & Bird

STARTUPCEO FORUM

M&A WORKSHOP

Timings: Feb 5, 11:00 - 12.30 - Synergy 2

This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge. Additional seats may be available on first-come first-served basis.

Co-Hosts:

A Chatham House Rule, invite-only forum for CEOs, CFOs, CBOs and chairmenof private life science and healthcare companies. The forum will feature peer-reviewed c-level and partner case studies, and an interactive general discussion.

The Private CEO Forum is only open to post series A private biotech companies. This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge.

Co-Hosts:

Timings: Feb 4, 13:45 - 15.30 - Synergy 2 Case Studies

Moderator:

Andrew Harrow, Partner, Goodwin

Case Study 1: Considerations and planning for going public in the US Assaf Homossany, MD-EMEA, Nasdaq

Case Study 2: Crossover Fundraising Strategies Sophie McGrath, Partner, Goodwin

Case Study 3: Successful US fundraising and IPOs

Matt Gline, CFO, Roivant

PRIVATECEO FORUM

Timings: Feb 5, 11:00 - 12.30 - Integrate 3

This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge. Additional seats may be available on first-come first-served basis.

Co-Hosts:

WORKSHOP

CLINICALSTRATEGIES



Lunch Break13:00

Growing opportunity, growing threat; cyber-security in the context of digitisation

Moderator: Bill Aronson, COO, AI Research Group Leon Lerman, CEO, Cynerio Saif Abed, Founding Partner, AbedGraham, Cyber Security Expert, European Commission and WHO Jovan Stevovic, CEO, Chino.io

Panel: Healthtech’s reimbursement challenge in the digital age

Moderator: Prof. Brian D Smith, Principal Advisor, Pragmedic Daniel O’Mahony, Partner, Seroba Life Sciences Luella Trickett, Director Value and Access, Association of British HealthTech Industries Rudy Dekeyser, Managing Partner, LSP Health Economics Fund Paul Brown, CFO, NW London CCGs, NHS Ali Hasan, Chief Medical and Health Officer, Vitality

Panel: PIPEs, pipelines and public equities

Panel: Platforms and partnerships

Moderator: Mick Cooper, Analyst, Trinity Delta Mattias Häggblom, Fund Manager, Swedbank Robur Geraldine O’Keeffe, Partner Public Equities, LSP Ulrica Slåne Bjerke, CIO, Arctic Aurora LifeScience Marek Poszepczynski, Portfolio Manager - International Biotechnology Trust, SV Health Investors

Moderator: Andy Smith, Analyst, Equity Development Yochi Slonim, CEO, Anima Biotech Tim Luker. Sr. Director External Innovation, Lilly Jane Dancer, CBO, F-Star Giuseppe Mazza, CEO, Engitix Mike Romanos, CEO, Microbiotica

Panel: The I in team - CEO strategy in C-Suite management & board development

Moderator: Melanie Senior, Analyst & Specialist Writer, Life SciencesDon DeBethizy, Director, Argenx and Chair to European biotechs Sarah Shackleton, Partner, Marketing & Talent, Abingworth Edwin Moses, former CEO, AblynxDenise Scots-Knight, CEO, Mereo Biopharma Annalisa Jenkins, Chair to European biotechs

Afternoon Keynote Panel: Health technology convergence - Driving the next wave of value in healthcare

Moderator: Andy Smith, Analyst, Equity Development Anoop Maini, CEO, Excite Ventures Sumit Nagpal, CEO and Co-Founder, CareFully Junaid Bajwal, Global Lead for Strategic Alliances, MSD Fireside Chat: Now and then - The true impact of AI on life sciences & realising AI potential

Mark O’Herlihy, Managing Director EMEA, IBM Watson Health Closing Keynote Panel: Realising AI’s potential in life sciences and healthcare Moderator: John Hodgson, Independent Consultant Derk Arts, CEO, Castor Bharat Tewarie, Former EVP & CMO, UCB Alison Howie, Chief Product Officer, IXICO Parker Moss, Board Member, CRUK

14:00

Closing Keynote Panel: Mapping Medtech’s future - New opportunities in collaboration and innovation

Moderator: Prof. Brian D Smith, Principal Advisor, Pragmedic Fredrik Strömberg, Senior Regional Director Northern Europe, Nobel BiocareEdward Cox, Digital Therapeutics CEO and Thought Leader , Dthera Sciences Christoffer-Martin Seubert, Lead for Strategic Alliances, Digital Health, Teamplay Platform, Siemens Healthineers Richard Kivel, Managing Director, GrayBella Capital Julie Bretland, CEO, Our Mobile Health Close of Congress

16:00

Fireside Chat: Fundraising and the real-world value in therapeutic AI Moderator: Bill Aronson, COO, AI Research GroupMarc Julien, Co-CEO, Diabeloop

12:20 12:10 11:50 12:40

Close of Congress16:20

14:45

15:10

14:00

14:40

15:30



https://www.lsxleaders.com/lsx-world-congress/workshops

1716

Presenter: Celia Belline, CEO Market/Indication: To accelerate the development of novel therapies to prevent and treat hearing loss, tinnitus, and otitis

Funding Stage: Growth, Private Development Stage: Pre-Clinical, Phase I, Phase II Location: France

Track: Inv¤$table BiotechDay and Time: Day 1, 16.30

Presenter: Jon H.Hoem, CEO & Co-Founder Market/Indication: The first medical device to diagnose and be a treatment platform for microvascular obstruction in heart attack patients

Funding Stage: Early Growth Development Stage: Phase I Location: Switzerland

Track: Inv¤$table MedtechDay and Time: Day 1. 16.00

Presenter: Neil Clark, CEO Market/Indication: Anti-infectives that prevent infection and improve outcomes for patients

Funding Stage: Publicly Listed Ticker: LON: DEST Development Stage: Drug Discovery, Phase II Location: United Kingdom Track: Inv¤$table BiotechDay and Time: Day 1, 14.15


Presenter: Cristianne Rijcken, Founder & CSO Market/Indication: Targeted nanomedicines with superior therapeutic profiles for the treatment of cancer

Funding Stage: Growth, Private Development Stage: Phase IILocation: Netherlands

Track: Licensable BiotechDay and Time: Day 1, 11.30

Presenter: Gaudenz von Capeller, CFO Market/Indication: Pritavely-owned Biopharma - patented small molecule drug with an innovative mode of action targeting NOTCH-driven cancers, and providing hope for patients with no other treatment options.

Funding Stage: Early Growth Development Stage: Phase I Location: Switzerland


Presenter: David Mazzo, CEO Market/Indication:Late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies

Funding Stage: Publicly Listed Ticker: NASDAQ:CLBS Development Stage: Phase II Location: United States


Presenter: Ajan Reginald, CEO Market/Indication:Devoted to discovering breakthrough medicines that change the standard of medical care for patients.

Funding Stage: Private Development Stage: Phase II Location: United Kingdom

Track: Cardio MetabolicDay and Time: Day 1, 14.15


Showcase Profiles

Presenter: Egill Masson, CEO Market/Indication: Development of therapeutics which enhance and deploy the body’s own innate microbial defence mechanisms to combat debilitating infectious diseases.

Funding Stage: Seed Development Stage: Drug Discovery, Pre-Clinical Location: Iceland


a

a




a

Presenter: Andy Yates, CSO Market/Indication: Endocannabinoid systemmodulation - oncology andcancer associated anorexia, IBD,rare diseases

Funding Stage: Publicly Listed Ticker: NASDAQ: ARTL Development Stage: Phase IILocation: United States


Presenter: Michael Malkoch, CEO Market/Indication: The most innovative fixation technology of bone fractures resulting in higher surgical success rate, faster recovery time and less pain suffering.

Funding Stage: Seed, Early Growth Development Stage: Clinical, In Development Location: Sweden

Track: Inv¤$table MedtechDay and Time: Day 1, 15.00

Presenter: Myles Greenberg, President & CEO Market/Indication: Transforming the way vascular disease is treated, naturally, with Natural Vascular Scaffolding™ (NVS).

Funding Stage: Early Growth Development Stage: Clinical, In Development Location: United States


Presenter: Catherine Schreiber, Dep. CEO Market/Indication: World’s first method for the combined multi-organ support of liver, lung, kidney, and acid-base balance.

Funding Stage: Early Growth, Growth Development Stage: On the Market, Clinical Location: Germany


Presenter: Michel Finance, CEO Market/Indication: Affluent Medical focuses on breakthrough therapies with a new approach of medical devices.

Funding Stage: Late Growth Development Stage: Clinical Location: France


Presenter: Claudia Jimenez, General Manager Market/Indication: Proprietary and patent protected technolgies to boost the production of recombinant proteins using Baculovirus vector expression systems (BVES) in insect cells.

Funding Stage: Growth Development Stage: Filing / Reg. Approval Location: Spain


Presenter: Yochi Slonim, Co-Founder & CEO Market/Indication: Translation Control Therapeutics, the first platform for the discovery of small molecule drugs that control mRNA translation.

Funding Stage: Early Growth Development Stage: Pre-Clinical Location: United States



Presenter: Ulf Hannelius, President & CEO Market/Indication: Develops the diabetes vaccine Diamyd®, an Antigen Based Therapy (ABT) based on the exclusively in-licensed GAD molecule.

Funding Stage: Publicly Listed Ticker: FRA:DMN Development Stage: Phase I, Phase II Location: Sweden


1918

Presenter: Richard Boyd, CEO Market/Indication: Improving outcomes for patients ondialysis, and other extra-corporeal treatments

Funding Stage: Early Growth Development Stage: Pre-Clinical Location: United Kingdom


Presenter: David Tuch, CEO Market/Indication:The company develops and markets molecular imaging and sensing technologies to enable surgeons to detect cancer in real time during surgery and improve health outcomes for cancer patients. Funding Stage: Growth Development Stage: Clinical Location: United Kingdom



Presenter: Grace E. Colón, President & CEO Market/Indication: Novel approach of treating cardiovascular conditions by the inhalation route.

Funding Stage: Early Growth, Private Development Stage: Phase II Location: United States


Presenter: Andrew Woodland, CSO Market/Indication: We are discovering the next generation of therapies for skin diseases, including eczema, non-melanoma skin cancers and orphan skin diseases.

Funding Stage: Seed Development Stage: Drug Discovery Location: United Kingdom


In4DermBecause Skin Matters

Presenter: Sijme Zeilemaker, COO Market/Indication: Novel immuno-oncology approach to treat solid tumours through its lead program Ilixadencel.

Funding Stage: Publicly Listed Ticker: STO: IMMU Development Stage: Phase II Location: Sweden


Presenter: Orest Lastow, CEO Market/Indication: ICONOVO is a Swedish privately funded device company with a business model to supply the market with unique, safe and cost efficient inhalation devices.

Funding Stage: Growth Development Stage: Filing / Reg. Approval, Clinical, In Development Location: Sweden


Presenter: Adam Robertson, CSO Market/Indication: Developing pharmaceuticals to treat glioblastoma multiforme patients. Hemispherian scientists have identified and are advancing compounds that are highly effective in treating these tumors.

Funding Stage: Seed Development Stage: Drug Discovery, Pre-Clinical Location: Norway


Presenter: Pascal Neuville, CEO Market/Indication: Transmembrane and G Protein-Coupled Receptor (GPCR) targeting for the discovery and development of innovative therapeutics for the treatment of CNS diseases and cancer.

Funding Stage: Early Growth, Private Development Stage: Drug Discovery, Pre-Clinical, Phase I, Phase II Location: France



Presenter: Michael Pehl, CEO Market/Indication: Discover, develop, manufacture and commercialize next generation immunotherapies for the treatment of cancer patients

Funding Stage: Seed, Private Development Stage: Pre-Clinical, Phase I Location: Germany


Presenter: Lorenzo Pradella, CEO Market/Indication: GreenBone is a leading bone regeneration company founded in 2014 addressing high unmet medical needs in the field of orthopaedics and bone diseases.

Funding Stage: Growth Development Stage: Filing / Reg. Approval, Clinical Location: Italy


Presenter: Juho Jalkanen, CDO Market/Indication: Clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs.

Funding Stage: Growth Development Stage: Phase II Location: Finland

Track: Licensable BiotechDay and Time: Day 1. 11.00

Presenter: Shlomi Raz, CEO Market/Indication: Dedicated to unlocking the therapeutic potential of serotonin 2A receptor agonists, commonly referred to as psychedelics, through the mitigation and management of psychoactivity

Funding Stage: Early Growth Development Stage: Drug Discovery, Pre-Clinical, Phase I, Phase II Location: United Kingdom


Presenter: Philip Huxley, CEO Market/Indication: Pre-clinical stage company aiming to develop novel therapies for inflammation and autoimmune disease.

Funding Stage: Seed Development Stage: Pre-Clinical Location: United Kingdom

Track: Licensable BiotechDay and Time: Day 1, 11:15

Presenter: Jan Alenfall, CEO Market/Indication: Our research and development is currently focused on the stimulation of hair growth and diabetes.

Funding Stage: Early Growth Development Stage: Drug Discovery, Phase II Location: Sweden

Track: Cardio MetabolicDay and Time: Day 1, 15:15

Presenter: Pete O’Heeron , CEO Market/Indication: Regenerative medicine company developing an innovative regenerative medicine solution for chronic diseases using fibroblasts.

Funding Stage: Early Growth, Private Development Stage: Phase IILocation: United States

Track: Licensable BiotechDay and Time: Day 1, 11.45


Presenter: Veronica Gambillara Fonck, CEO Market/Indication: Translating novel scientific concepts into early proof of concepts for both the prevention and treatment of life-threatening diseases.

Funding Stage: Seed Development Stage: Drug Discovery Location: Switzerland



Presenter: Hannoch Markshied, CEO Market/Indication: Innovative sealants and surgical patches based on unique combinations of advanced bioactive materials and optimized, electrospun nanofiber matrices.

Funding Stage: Early Growth Development Stage: Clinical Location: Israel


Presenter: Denis Dufrane, CSO /Co-Founder Market/Indication: Novadip has developed a unique tissue regeneration platform capable of generating multiple product classes to transform the lives of patients with limited or no effective treatment options.

Funding Stage: Private Development Stage: Phase II Location: Belgium


Presenter: David Urech, CEO Market/Indication: Offering cutting-edge discoveryof ready-to-develop multispecificbiotherapeutics to partners.

Funding Stage: Growth Development Stage: Drug Discovery, Pre-Clinical, Phase I Location: Switzerland

Track: Inv¤$table Biotech 2Day and Time: Day 1, 16:30

Presenter: Lorenzo Rossi, CEO Market/Indication: Newronika builds innovative brain devices based on its large knowledge on biosignal decoding

Funding Stage: Early Growth Development Stage: Filing / Reg. Approval, Clinical Location: Italy


Presenter: Brian Shields, CEO Market/Indication: Minimally invasive hand-held radio- frequency device which ENT surgeons will use to treat patients in an office setting, removing the complications and costs associated with most surgical procedures.

Funding Stage: Early Growth Development Stage: Clinical, Location: Ireland


Presenter: Natalia Perekhvatova, CEO Market/Indication: Rapid development of break-through pharmaceutical products based on mitochondria targeted antioxidants.

Funding Stage: Growth Development Stage: Phase III Location: Luxembourg


Presenter: John Burt, CEO Market/Indication: Medherant has built upon its founders’ world-leading expertise in bio-adhesives and polymer chemistry to create its unique patent protected TEPI Patch® drug delivery technology.

Funding Stage: Early Growth Development Stage: Pre-Clinical Location: United Kingdom


Presenter: Leonie De Best, CBO Market/Indication: Pre-clinical stage biotech company, developing novel antibiotics, so called Synthetic Anti-Microbial and Anti-Biofilm Peptides (SAAPs) to combat a wide variety of (resistant) bacterial infections.

Funding Stage: Seed Development Stage: Pre-Clinical Location: Netherlands

Track: Inv¤$table Biotech 2Day and Time: Day 1, 16:15

Presenter: Oren Glanz, CEO Market/Indication: We are a pre-clinical biotech company, pioneering a paradigm shift in the modification of the innate immune system to effectively combat severe diseases.

Funding Stage: Seed Development Stage: Drug Discovery, Pre-Clinical Location: Israel Track: Cardio MetabolicDay and Time: Day 1, 14.30

T H E R A P E U T I C S

L E M P O


Presenter: Christina Herder, EVP, COO Market/Indication: Medivir is a drug discovery and development company focusing on transformative cancer drugs.

Funding Stage: Publicly Listed Ticker: STO: MVIR-B Development Stage: Phase I, Phase II Location: Sweden


Presenter: Barry Sharples, Chairman Market/Indication: Focused out of the public eye for 7 years, developing what we believe to be a paradigm shift in stem cell science.

Funding Stage: Growth, Private Development Stage: Pre-Clinical, Phase I/II Location: United Kingdom

Track, Day and Time: Inv¤$table Biotech, Day 1, 11.15, Cardio Metabolic, Day 1, 15.00

Presenter: Mike Romanos, CEO Market/Indication: Microbiotica has programs in IBD, immune-oncology and Clostridium difficile, developing medicines and biomarkers based on microbiota.

Funding Stage: Early Growth Development Stage: Drug Discovery, Pre-Clinical Location: United Kingdom


Presenter: Begüm Utz, Product Manager Market/Indication: Improving the diagnosis, treatment and prevention of acute neurodegenerative conditions and is currently focused ondeveloping a diagnostic kit for the detection of Traumatic Brain Injury.

Funding Stage: Early Growth Development Stage: Phase II Location: Finland


Presenter: Konstantin Chernov, CEO Market/Indication: We investigate transport- and binding functions of albumin in the blood with the aim to improve the diagnostic of life-threatening diseases

Funding Stage: Early Growth, Private Development Stage: Pre-Clinical, Filing / Reg. Approval, On the Market, Clinical, In Development Location: Germany



Presenter: Martin Olovsson, CEO Market/Indication: The OnDosis device offers a new way to deliver prescription treatment: integrating medicine with intelligent dosing.

Funding Stage: Seed, Early Growth Development Stage: Filing, Reg. Approval, In Development Location: Sweden


Presenter: Ewen Northwood, Director Market/Indication: NirVisio is developing and will commercialise a family of Near Infra-Red (NIR) imaging devices that will transform dental healthcare by improving the detection and monitoring of dental caries

Funding Stage: Pre-Seed Development Stage: Pre-Clinical Location: United Kingdom


2322

Presenter: Attila Borbath, CEO Market/Indication: We are pioneering optoelectronics for neurostimulation medical devices by developing innovations to provide a powerful and versatile neurostimulation technological platform.

Funding Stage: Growth Development Stage: Pre-Clinical Location: Belgium

Track: Inv¤$table MedtechDay and Time: Day 1, 11:45


Presenter: Andrew Parker, CEO Market/Indication: Step Pharma is a biotechnology company discovering and developing proprietary small molecule therapeutics for thetreatment of auto-immune diseases.

Funding Stage: Early Growth Development Stage: Pre-Clinical Location: France


step pharma step pharma

Presenter: Halvor Celius, CEO Market/Indication: SonoClear is developing a product for enhanced ultrasound image quality in brain tumor surgery, providing the neurosurgeon with a powerful tool to achieve complete tumor removal.

Funding Stage: Seed / Private Development Stage: In Development Location: Norway


Presenter: Jack Lee, CEO Market/Indication: Ring-type Cardio Tracker, CART to help continuous monitoring of atrial fibrillation which is difficult to diagnose even in a hospital in daily life.

Funding Stage: Early Growth Development Stage: Phase III, Filing / Reg. Approval Location: South Korea


Presenter: Suzanne Saffie-Siebert, CEO Market/Indication: ProSilic® is our bio-courier engineered to maximise the therapeutic benefits of drug molecules and active ingredients.

Funding Stage: Growth Development Stage: Pre-Clinical Location: United Kingdom Track: Inv¤$table BiotechDay and Time: Day 1, 17.00

Presenter: Nawal Ouzren, CEO Market/Indication: Biopharmaceutical company developing life-transforming therapies for patients with inner ear disorders involving vertigo and hearing loss.

Funding Stage: Publicly Listed Ticker: ENX:ALSEN Development Stage: Pre-Clinical, Phase II Location: France

Track: Inv¤$table Biotech 2Day and Time: Day 1, 16.00

Presenter: Yoav Lichtenstein, CEO Market/Indication: State-of-the-art innovative practical GI endoscopy solutions, Versatile, on-demand, easy-to-assemble, cost-effective, colonoscopy assist device.

Funding Stage: Seed Development Stage: In development Location: Israel


Presenter: Carlos Buesa, CEO Market/Indication: Oryzon is a public clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics.

Funding Stage: Publicly Listed Development Stage: Phase II Ticker: BME: ORY Location: Spain


Presenter: Stuart Collinson, CEO Market/Indication: OxStem is developing small molecule therapeutics targeting innate regeneration and repair.

Funding Stage: Early Growth Development Stage: Drug Discovery Location: United Kingdom



Presenter: Ivo Timmermans, CEO Market/Indication: Dutch private limited company, established to develop a portfolio of therapies in the field of cancer medicine.

Funding Stage: Seed Development Stage: Pre-Clinical Location: Netherlands


Presenter: Cliff Holloway, CEO Market/Indication:Scancell is focused on developing innovative immunotherapies for cancer that stimulate the body’s own immune system.

Funding Stage: Publicly Listed Ticker: LON: SCLP Development Stage: Pre-Clinical, Phase I, Phase II Location: United Kingdom


Presenter: Mark Rushworth, MD Market/Indication: SageTech has developed a comprehensive way to capture, extract and purify volatile anaesthetic gases to PhEur monograph standard.

Funding Stage: Seed Development Stage: Filing / Reg. Approval, Clinical Location: United Kingdom


Presenter: Lone Veng, CEO Market/Indication: Focused on developing peptide-based drugs derived from the endogenous immunomodulator Annexin A1 as resolution therapy

Funding Stage: Early Growth Development Stage: Drug Discovery, Pre-Clinical Location: Denmark


Presenter: Julian Howell, Co-Founder & CEO Market/Indication:We are an early-stage research and development company — our mission is to save kidneys and prevent pain in people with Cystinuria.

Funding Stage: Seed Development Stage: Pre-Clinical Location: United Kingdom



Presenter: Nikolaos Deliolanis, CEO Market/Indication: Thericon is the first to bring multiparametric imaging to the operating theater. This allows for displaying of previously invisible tissue properties together with standard color images on a single screen.

Funding Stage: Seed, Private Development Stage: Clinical, In Development Location: Germany


Presenter: David Yudovich, CEO Market/Indication: Full scope gene editing analysis solution that combines proprietary sequencing algorithms together with cost-effective, immediate access, and rapid turnaround sample processing services.

Funding Stage: Seed Development Stage: Pre-Clinical, On the Market, In Development Location: Sweden


2524

Presenter: Piers Morgan, CFO Market/Indication: Focused on the development and commercialization of innovativeprescription medicines to treat respiratory diseases.

Funding Stage: Publicly Listed Ticker: AIM:VRP Development Stage: Phase II Location: United Kingdom



Presenter: Vincent Forster, CEO Market/Indication: Versantis develops a new generation of liver disease therapeutics and diagnostics.

Funding Stage: Growth Development Stage: Phase ILocation: Switzerland




The Digital Poster Innovation Zone hosted by MSD runs across both days and is an opportunity to connect with and explore the next generation of bio and medical technologies being developed by entrepreneurs from across Europe’s leading TTOs. Digital posters can be viewed at any time throughout the conference.

Discover the life science executive leaders of tomorrow!

Sinntaxis

Sinntaxis

INNOVATIONZONE

HOSTED BY:

INVENTING FOR LIFE

MorphGI


DIOGEN

Presenter: Michael Stein, CEO Market/Indication: Immuno-oncology company developing novel, rapidly adaptable therapeutic cancer immunotherapies using its patented PeptiCRAd and PeptiENV platforms.

Funding Stage: Early Growth Development Stage: Pre-Clinical Location: Finland


Presenter: Eliane Schutte, CEO Market/Indication: Xeltis is a clinical-stage medical device company pioneering a restorative approach in cardiovascular therapy.

Funding Stage: Growth Development Stage: Clinical Location: Netherlands / Switzerland



Onsite Networking Opportunities

Networking Party

What’s an event without some fun? The World Congress networking party on the evening of day one is the perfect opportunity to unwind, let your hair down and informally network with the community.

Relax, network and make unexpected connections over a drink (or few!).

Investor Dinner

If you have purchased a ticket to the Investor-only dinner, you will be directed from the conference venue at approx. 7pm to the dinner venue for a gourmet 3-course networking dinner. Your badge will confirm you have a seat reserved. This dinner required pre-registration and is a sell out.

Maximise your out-of-session networking time and secure those vital face-to-face meetings. The partnering system went live with your profile filled in from the information provided on registration and allows you to search for potential partners and book meetings in the extensive 1-2-1 partnering area.

1:1 Partnering



Industry Leading Events for the Life Science C-suite

2-3 September 2020, Nasdaq Offices, Stockholm, Sweden www.lsxleaders.com/nordic

16-17 November 2020, Old Billingsgate, London, UK www.lsxleaders.com/digihealth

16 November 2020, Old Billingsgate, London, UK www.lsxleaders.com/investival

17 November 2020, The Honourable Artillery Company, London, UK www.lsxleaders.com/lifestars

21-22 April 2020, etc. venues, 133 Houndsditch, London, UK www.longevityleaders.com

WORLDCONGRESS

2-3 February 2021, etc. venues, 133 Houndsditch, London, UK www.lsxleaders.com/world

HOSTED BY:

HOSTED BY:

http://www.lsxleaders.com/world


Congress & Exhibition Floorplan

CONGRESS - LSX Home Brochure.pdf · There is a whole host of benefits to downloading the app:...

Documents

Transcript of CONGRESS - LSX Home Brochure.pdf · There is a whole host of benefits to downloading the app:...